| Defining "adequate" pathogen reduction performance for transfused blood components. | |
| | |
MedLine Citation:
|
PMID: 20374558 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pathogen reduction of labile blood products offers the opportunity to introduce to the blood banking community the same mechanism of protection that is employed for fractionated or pooled plasma products today--blood components that have been treated with methods to inactivate or reduce the infectivity of a variety of organisms that may contaminate donated blood and thus potentially transmit infection via transfusion. Due to the mechanisms of action, the methods employed in the plasma fractionation environment are not directly applicable to labile blood products. This article examines whether the same criteria of performance required for plasma derivatives (i.e., 6 log/mL reduction by multiple orthogonal methods) should be applied to the treatment of labile components and if not what criteria for performance might be sufficient. In conducting this analysis, we have considered what has been learned in the past several decades regarding the dynamics and infectivity of various pathogens and disease transmission by blood products, the introduction and progressive enhancement of testing methods based on serology and nucleic acid testing, and the performance characteristics for pathogen reduction technologies that are available today. |
| | |
Authors:
|
Raymond P Goodrich; Brian Custer; Shawn Keil; Michael Busch |
Related Documents
:
|
10160338 - Medicare and medicaid programs; hospital standard for potentially hiv infectious blood ... 12009968 - Novel method for detecting bovine immunoglobulin g in dried porcine plasma as an indica... 20562138 - A review of blood product usage in a large emergency department over a one-year period. 9085538 - Blood substitutes for transfusion. 12508378 - Role of nf-kb in multiple organ dysfunction during acute obstructive cholangitis. 9083638 - Crosslinked hemoglobin-superoxide dismutase-catalase scavenges free radicals in a rat m... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Transfusion Volume: 50 ISSN: 1537-2995 ISO Abbreviation: Transfusion Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-10-07 Completed Date: 2010-10-22 Revised Date: 2011-03-14 |
Medline Journal Info:
|
Nlm Unique ID: 0417360 Medline TA: Transfusion Country: United States |
Other Details:
|
Languages: eng Pagination: 1827-37 Citation Subset: IM |
Affiliation:
|
CaridianBCT Biotechnologies, LLC, Lakewood, Colorado 80215, USA. ray.goodrich@caridianbct.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bacteremia
/
microbiology Blood Component Transfusion / adverse effects, methods* Blood-Borne Pathogens / isolation & purification* Humans Parasitemia / parasitology Viremia / virology Virus Replication |
| Comments/Corrections | |
Comment In:
|
Transfusion. 2010 Aug;50(8):1636-9
[PMID:
20883251
]
Transfusion. 2011 Feb;51(2):446-7; author reply 447-8 [PMID: 21309785 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: S100A10-mediated translocation of annexin-A2 to SNARE proteins in adrenergic chromaffin cells underg...
Next Document: Reaching rural Africans with eye care services: findings from primary eye care approaches in Rubavu ...